
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **September 19, 2013**

Heat Biologics, Inc.

(Exact name of registrant as specified in its charter)

Delaware
*(State or Other Jurisdiction
of Incorporation)*

001-35994
*(Commission
File Number)*

26-2844103
*(I.R.S. Employer
Identification No.)*

**100 Europa Drive
Chapel Hill, NC 27517**
(Address of Principal Executive Office) (Zip Code)

(919) 240-7133
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-
-
-

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 19, 2013, the Board of Directors of Heat Biologics, Inc. (the “Company”) voted to increase the size of the Board of Directors to six and appointed Louis C. Bock to fill the vacancy on the Board. Mr. Bock has been named to serve on the audit committee of the Board to replace Mr. Wolf. Mr. Bock qualifies as an “audit committee financial expert” as that term is used in Section 407 of the Sarbanes-Oxley Act of 2002. Mr. Bock is independent in compliance with the applicable rules of the NASDAQ. For his service as directors of the Company, Mr. Bock will receive the Company’s standard compensation applicable to nonemployee directors.

There are no family relationships between Mr. Bock and any director, executive officer or person nominated or chosen by the Company to become as director or executive officer. Additionally, there have been no transactions involving Mr. Bock that would require disclosure under Item 404(a) of Regulation S-K.

Item 8.01 Other Events.

On September 25, 2013 the Company issued a press release announcing the appointment of Mr. Bock as a director of the Company. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

<u>Exhibit Number</u>	<u>Description</u>
<u>99.1</u>	Press Release, dated September 25, 2013*

*Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Dated: September 25, 2013

HEAT BIOLOGICS, INC.

By: /s/ Jeff Wolf

Name: Jeff Wolf

Title: Chairman, President and
Chief Executive Officer

EXHIBIT INDEX

**Exhibit
Number**

Description

[99.1](#)

Press Release, dated September 25, 2013



Heat Biologics Appoints Louis C. Bock to Board of Directors

CHAPEL HILL, NC (September 25, 2013): Heat Biologics, Inc. (Nasdaq: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, today announced that it has appointed industry veteran Louis C. Bock to its Board of Directors.

“We welcome Lou to Heat Biologics and I look forward to relying on his experience as an accomplished biotechnology executive and investor at this exciting juncture in our corporate history,” said Jeff Wolf, Chief Executive Officer of Heat Biologics.

Mr. Bock is currently a Partner of venture capital firm, Scale Venture Partners, where he manages a portfolio of biopharmaceutical investments. Prior to joining Scale Venture Partners, Mr. Bock was at Gilead Sciences and Genentech where he held senior-level positions in research, project management, business development and sales. Lou sits on the Boards of Ascenta Therapeutics, New Century Hospice, Orexigen Therapeutics, Sonexa Therapeutics and Zogenix. He was also responsible for ScaleVP’s investments in Dynavax Technologies (NASDAQ: DVAX), Prestwick Pharmaceuticals, Seattle Genetics (NASDAQ: SGEN) and Somaxon (NASDAQ: SOMX).

“I am impressed by the Company’s immunotherapy approach and look forward to working with Jeff and the team as Heat Biologics continues to move its novel ImPACT Therapy through the clinic with the goal of improving therapeutic outcomes for cancer patients,” said Mr. Bock.

About Heat Biologics:

Heat Biologics (www.heatbio.com) is a clinical-stage biopharmaceutical company focused on developing its novel off-the-shelf *ImPACT* therapeutic vaccines to combat a wide range of cancers. Our proprietary *ImPACT* Therapy is being designed to deliver live, genetically-modified, irradiated human cells which are reprogrammed to “pump out” a broad spectrum of cancer-associated antigens together with a potent immune adjuvant called “gp96” to educate and activate a cancer patient’s immune system to recognize and kill cancerous cells. Heat shock protein gp-96 is a chaperone protein found in all human cells. Heat’s lead compound, HS-110, will be entering Phase 2 trials against non-small cell lung cancer and its second product candidate, HS-410 will be entering Phase 1/2 clinical trials against bladder cancer.

This release includes forward-looking statements on our current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and include statements regarding Heat’s continued clinical trials and its goals. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the expected contribution Mr. Bock. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.

###

Heat Biologics, Inc. Contact Information:

Matthew Czajkowski
Chief Financial Officer
(919) 240 7133
matt@heatbio.com

Rhonda Chiger
Rx Communications Group
(917) 322-2569
rchiger@rxir.com